A comprehensive view of Branded Drugs. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

GSK updates prescribing information for the ovarian cancer drug Zejula, limiting use to second-line maintenance therapy only to patients with certain mutation types; change was made at the request of FDA following review of Phase 3 clinical results

AstraZeneca and Daiichi Sankyo’s Enhertu injection recommended for approval in the EU as a treatment for certain type of gastric cancer; drug is currently approved in the US

AstraZeneca’s Imfinzi recommended in the EU for approval as a first-line treatment for unresectable or metastatic biliary tract cancer; treatment is used in combination with chemotherapy

AstraZeneca and MSD's Lynparza combined with abiraterone and prednisone or prednisolone has been recommended in the EU for approval as a treatment for metastatic castration-resistant prostate cancer

JPMorgan rates Gilead as overweight, noting its emerging oncology business, and expecting HIV franchise to grow low single-digit CAGR though early 2030s; Biktarvy to remain dominant product with revenues growing from US$10.2B in 2022 to US$12.5B in 2025

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count